{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T14:17:18Z","timestamp":1772288238921,"version":"3.50.1"},"reference-count":14,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["18KK0439"],"award-info":[{"award-number":["18KK0439"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["20K08139"],"award-info":[{"award-number":["20K08139"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","award":["JPMXS0422500320"],"award-info":[{"award-number":["JPMXS0422500320"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.xphs.2023.02.025","type":"journal-article","created":{"date-parts":[[2023,3,4]],"date-time":"2023-03-04T18:26:17Z","timestamp":1677954377000},"page":"1740-1745","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Development of Triple-Negative Breast Cancer-Targeted Liposomes with MUC16 Binding Peptide Ligand in Triple-Negative Breast Cancer Cells"],"prefix":"10.1016","volume":"112","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2371-911X","authenticated-orcid":false,"given":"Masayori","family":"Hagimori","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8233-5426","authenticated-orcid":false,"given":"Naoya","family":"Kato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Orimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadaharu","family":"Suga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8765-2463","authenticated-orcid":false,"given":"Shigeru","family":"Kawakami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.xphs.2023.02.025_bib0001","doi-asserted-by":"crossref","first-page":"46","DOI":"10.2478\/v10019-010-0054-4","article-title":"Triple negative breast cancer - prognostic factors and survival","volume":"45","author":"Ovcaricek","year":"2011","journal-title":"Radiol Oncol"},{"key":"10.1016\/j.xphs.2023.02.025_bib0002","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.21881","article-title":"Evaluation of adjuvant treatments for T1 N0 M0 triple-negative breast cancer","volume":"3","author":"Zhai","year":"2020","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.xphs.2023.02.025_bib0003","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1200\/JCO.2007.14.4147","article-title":"Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer","volume":"26","author":"Liedtke","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.xphs.2023.02.025_bib0004","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1080\/14728222.2018.1498845","article-title":"MUC16 as a novel target for cancer therapy","volume":"22","author":"Aithal","year":"2018","journal-title":"Expert Opin Ther Targets"},{"key":"10.1016\/j.xphs.2023.02.025_bib0005","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0161290","article-title":"Selection of novel peptides homing the 4T1 cell line: exploring alternative targets for triple negative breast cancer","volume":"11","author":"Silva","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.xphs.2023.02.025_bib0006","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1248\/cpb.c17-00098","article-title":"Peptide-based cancer-targeted DDS and molecular imaging","volume":"65","author":"Hagimori","year":"2017","journal-title":"Chem Pharm Bull"},{"key":"10.1016\/j.xphs.2023.02.025_bib0007","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.ijpharm.2017.02.041","article-title":"Ligand peptide-grafted PEGylated liposomes using HER2 targeted peptide-lipid derivatives for targeted delivery in breast cancer cells: the effect of serine-glycine repeated peptides as a spacer","volume":"521","author":"Suga","year":"2017","journal-title":"Int J Pharmaceutics"},{"key":"10.1016\/j.xphs.2023.02.025_bib0008","doi-asserted-by":"crossref","first-page":"4481","DOI":"10.1021\/acs.molpharmaceut.8b00476","article-title":"Development of high-functionality and -quality lipids with RGD peptide ligands: application for PEGylated liposomes and analysis of intratumoral distribution in a murine colon cancer model","volume":"15","author":"Suga","year":"2018","journal-title":"Mol Pharm"},{"key":"10.1016\/j.xphs.2023.02.025_bib0009","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ejps.2018.07.036","article-title":"Synthesis of high functionality and quality mannose-grafted lipids to produce macrophage-targeted liposomes","volume":"123","author":"Hagimori","year":"2018","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.xphs.2023.02.025_bib0010","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.jddst.2018.12.037","article-title":"Synthesis of a high functionality and quality lipid with gp130 binding hydrophobic peptide for the preparation of human glioma cell-targeted","volume":"49","author":"Suga","year":"2019","journal-title":"J Drug Deliv Sci Technol"},{"key":"10.1016\/j.xphs.2023.02.025_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2022.106239","article-title":"Synthesis and evaluation of a novel adapter lipid derivative for preparation of cyclic peptide-modified PEGylated liposomes: application of cyclic RGD peptide","volume":"176","author":"Kato","year":"2022","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.xphs.2023.02.025_bib0012","first-page":"3087","article-title":"Comparative study of the in vitro and in vivo characteristics of cationic and neutral liposomes","volume":"6","author":"Zhao","year":"2011","journal-title":"Int J Nanomedicine"},{"key":"10.1016\/j.xphs.2023.02.025_bib0013","doi-asserted-by":"crossref","first-page":"4265","DOI":"10.3390\/cancers13174265","article-title":"Targeting CA-125 transcription by development of a conditionally replicative adenovirus for ovarian cancer treatment","volume":"13","author":"Yue","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.xphs.2023.02.025_bib0014","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.addr.2015.01.003","article-title":"Are caveolae a cellular entry route for non-viral therapeutic delivery systems?","volume":"91","author":"Rewatkar","year":"2015","journal-title":"Adv Drug Deliv Rev"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354923000977?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354923000977?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T09:41:58Z","timestamp":1758361318000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354923000977"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":14,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["S0022354923000977"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2023.02.025","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of Triple-Negative Breast Cancer-Targeted Liposomes with MUC16 Binding Peptide Ligand in Triple-Negative Breast Cancer Cells","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2023.02.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 American Pharmacists Association. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}